Allison Naleway to Uterine Cervical Neoplasms
This is a "connection" page, showing publications Allison Naleway has written about Uterine Cervical Neoplasms.
Connection Strength
1.897
-
Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort. PLoS One. 2015; 10(2):e0117525.
Score: 0.453
-
Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
Score: 0.414
-
Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt). 2012 Apr; 21(4):425-32.
Score: 0.365
-
Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015-2017. J Low Genit Tract Dis. 2022 Apr 01; 26(2):135-139.
Score: 0.186
-
Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019 06 27; 37(29):3918-3924.
Score: 0.152
-
Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study. PLoS One. 2017; 12(1):e0165276.
Score: 0.129
-
Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
Score: 0.100
-
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
Score: 0.098